CStone Pharmaceuticals Unveils Promising Preclinical Data for Three Innovative ADCs at AACR 2026#China#Suzhou#ADC_technology#CStone_Pharmaceuticals#CS5007#CS5006#CS5008
CStone Pharmaceuticals Unveils Promising Preclinical Data for Three Innovative ADCs at AACR 2026
CStone Pharmaceuticals presents groundbreaking preclinical findings for three advanced ADCs at AACR 2026, promising enhanced treatment options for various cancers.
third-news.com
April 20, 2026 at 12:20 AM
CStone Pharmaceuticals Unveils Promising Preclinical Data for Three Innovative ADCs at AACR 2026#China#Suzhou#ADC_technology#CStone_Pharmaceuticals#CS5007#CS5006#CS5008
🔴 CStone dropped preclinical data on not one, but three ADCs at AACR, including CS5007, which targets EGFR/HER3. Think double trouble for tumors. If it works, big pharma should start sweating. #Biotech is heating up. Read it. Get it. Share it. #mikronews
April 20, 2026 at 12:18 PM
🔴 CStone dropped preclinical data on not one, but three ADCs at AACR, including CS5007, which targets EGFR/HER3. Think double trouble for tumors. If it works, big pharma should start sweating. #Biotech is heating up. Read it. Get it. Share it. #mikronews
Thoughts on this? >> CStone Presents Preclinical Results of CS2011 (EGFR/HER3
bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005
(SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR >> Comment below! #IoT #mhealth #AI #industry40 #healthtech
bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005
(SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR >> Comment below! #IoT #mhealth #AI #industry40 #healthtech
CStone Presents Preclinical Results of CS2011 (EGFR/HER3
bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005
(SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR
SUZHOU, China, May 6, 2025 /PRNewswire/ — CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC), key assets in CStone Pipeline 2.0, have been delivered at the 2025 …
dlvr.it
May 7, 2025 at 2:06 AM
Thoughts on this? >> CStone Presents Preclinical Results of CS2011 (EGFR/HER3
bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005
(SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR >> Comment below! #IoT #mhealth #AI #industry40 #healthtech
bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005
(SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR >> Comment below! #IoT #mhealth #AI #industry40 #healthtech